American College of Chest Physicians releases new clinical guidelines on EBUS-guided TBNA

NewsGuard 100/100 Score

The American College of Chest Physicians announced the release of new clinical guidelines on endobronchial ultrasound (EBUS)-guided transbronchial needle aspiration (TBNA). The guideline, which applies to a common bronchoscopic test, contains 12 recommendations including best practices related to patient factors and procedural aspects.

Endobronchial ultrasound (EBUS) was introduced in the last decade, enabling real-time guidance for transbronchial needle aspiration (TBNA) of structures located near the lung airways and providing a highly accurate and reliable way to diagnose conditions such as lung cancer, sarcoidosis, and TB. EBUS-TBNA has become an essential tool for pulmonologists and thoracic surgeons and is one of the recommended first steps in the mediastinal staging of lung cancer as outlined in Diagnosis and Management of Lung Cancer, 3rd ed, American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

"This guideline provides advice on optimal performance of EBUS-TBNA and examines current knowledge of the technical aspects of the procedure. EBUS-TBNA has become an essential tool for the chest physician, and guidance is needed as clinicians adopt its use for diagnosing pulmonary diseases," said Momen Wahidi, MD, MBA, Director, Interventional Pulmonology and Bronchoscopy, Duke University Medical, chair of the guideline panel.

The guidelines have been endorsed by the American Association of Bronchology and Interventional Pulmonology, American Association for Thoracic Surgery, European Association for Bronchology and Thoracic Surgery, and the Society of Thoracic Surgeons.

Source: American College of Chest Physicians

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Insilico Medicine's AI-driven approach yields promising PTPN2/N1 inhibitor for cancer immunotherapy